Development of fully bio-based pectin/curcumin@bio-MOF-11 for colon specific drug delivery.

The current study is carried out on curcumin delivery, which is recognized as an anticancer drug, to cancerous cells through a bio-metal–organic framework (bioMOF). After being immersed within the drug solution, the process of curcumin encapsulation was conducted in the porous bio-MOF-11. Furthermore, both protecting and carrying curcumin encapsulated bio-MOF-11 nanohybrid (curcumin@bio-MOF-11) within the gastrointestinal tract (GIT) were carried out using pH-sensitive pectin biopolymer. There were two different approaches applied to identify the pectin-coated curcumin@bio-MOF-11bio-nanocomposite hydrogel bead (pectin/curcumin@bio-MOF-11). Using the simulated GIT conditions, in-vitro drug release tests were conducted to illustrate the pectin/curcumin@bio-MOF-11effectiveness that was applied to the process of curcumin controlled delivery as a new carrier. Consequently, results showed that there was a constant release associated with pectin/curcumin@bio-MOF-11 under GIT conditions. Moreover, considerable toxicity of pectin/curcumin@bio-MOF-11 against human colon carcinoma cells was confirmed through the MTT test. Results implied that provided bio-nanocomposite hydrogel beads could act as appropriate drug delivery systems of curcumin colonic drug release. [ABSTRACT FROM AUTHOR]